Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima.
Pediatric Rheumatology Unit, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa.
ARP Rheumatol. 2022 Jan-Mar;1(1):12-20.
To identify predictive factors of relapse after discontinuation of Methotrexate (MTX) in Juvenile Idiopathic Arthritis (JIA) patients with inactive disease.
We conducted a prospective multicenter cohort study of patients diagnosed with JIA using real world data from the Portuguese national register database, Reuma.pt. Patients with JIA who have reached JADAS27 inactive disease and discontinued MTX before the age of 18 were evaluated.
A total of 1470 patients with JIA were registered in Reuma.pt. Of the 119 bionaive patients who discontinued MTX due to inactive disease, 32.8% have relapsed. Median time of persistence (using the Kaplan-Meier method and log-rank tests) with inactive disease was significantly higher in patients with more than two years of remission before MTX discontinuation and in those who did not use NSAIDs at time of MTX discontinuation. In Cox regression analyses and after adjustment for age at diagnosis, MTX tapering and JIA category, the use of NSAIDs at the time of MTX discontinuation (HR, 1.98 95%CI 1.03-3.82) and remission time of less than two years before suspension (HR, 3.12 95%CI 1.35-7.13) remained associated with relapse. No association was found between JIA category or the regimen of MTX discontinuation and the risk of relapse.
In this large cohort we found that the use of NSAIDs at the time of MTX discontinuation was associated with a two times higher likelihood of relapse. In addition, longer duration of remission before MTX withdrawal reduces the chance of relapse in bionaive JIA patients.
确定处于疾病缓解期的幼年特发性关节炎(JIA)患者停止使用甲氨蝶呤(MTX)后复发的预测因素。
我们进行了一项前瞻性多中心队列研究,纳入了葡萄牙国家登记数据库 Reuma.pt 中的 JIA 患者的真实世界数据。研究对象为达到 JADAS27 疾病缓解且在 18 岁前停止使用 MTX 的 JIA 患者。
Reuma.pt 共登记了 1470 例 JIA 患者。在因疾病缓解而停用 MTX 的 119 例生物制剂初治患者中,有 32.8%复发。使用 Kaplan-Meier 法和对数秩检验进行中位无疾病持续时间(persistence)评估,结果显示在 MTX 停药前缓解时间超过 2 年和 MTX 停药时未使用非甾体抗炎药(NSAIDs)的患者中,疾病缓解持续时间更长。在 Cox 回归分析中,在校正诊断年龄、MTX 减量和 JIA 类型后,MTX 停药时使用 NSAIDs(HR,1.98;95%CI,1.03-3.82)和停药前缓解时间不足 2 年(HR,3.12;95%CI,1.35-7.13)与复发相关。JIA 类型或 MTX 停药方案与复发风险之间未发现关联。
在这项大型队列研究中,我们发现 MTX 停药时使用 NSAIDs 与复发风险增加两倍相关。此外,MTX 停药前缓解时间延长可降低生物制剂初治 JIA 患者的复发几率。